EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives

Pasquale Degennaro, Imane Ghafir El Idrissi iD, Rosa Purgatorio iD, Annalisa Fanizzi, Mariagrazia Rullo iD, Leonardo Pisani iD, Eleonora Macchia, Luisa Torsi, Angela Stefanachi iD, Francesco Leonetti iD

Pharmaceuticals · 26.08.2026 · 19 (9) · 1352

DOI: 10.3390/ph19091352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 26.08.2026. Verfasst von Pasquale Degennaro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Italian Network of Excellence for Advanced Diagnosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional molecules that induce the selective degradation of a protein of interest by recruiting an E3 ubiquitin ligase, thereby triggering ubiquitination and proteasomal clearance. As part of the broader targeted protein degradation (TPD) paradigm, PROTACs offer a powerful strategy to eliminate pathogenic proteins that are difficult to modulate with traditional occupancy-based inhibitors. However, their clinical translation is often limited by poor aqueous solubility, suboptimal cellular permeability, and off-target effects. Notably, some PROTACs retain potent biological activity despite limited membrane permeability, owing to their catalytic mechanism of action, which allows even a small number of molecules reaching the target site to drive substantial protein degradation and produce important pharmacological effects. Growing evidence supports the application of PROTAC-based approaches in neurodegenerative diseases, where the selective removal of toxic or misfolded proteins is particularly attractive. This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.

Schlagwörter

Stichwörter der Autor:innen

Proteolysis-Targeting Chimeras (PROTACs)multi-target strategiesneurodegenerative diseasestargeted protein degradation (TPD)

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy.
  • Department of Chemistry, University of Bari Aldo Moro, 70125 Bari, Italy.

ORCID-Profile: Imane Ghafir El Idrissi, Rosa Purgatorio, Mariagrazia Rullo, Leonardo Pisani, Angela Stefanachi, Francesco Leonetti

Förderung

  • Ministry of Health
  • Italian Network of Excellence for Advanced Diagnosis

Zitieren

APA

Degennaro, P., Ghafir El Idrissi, I., Purgatorio, R., Fanizzi, A., Rullo, M., Pisani, L., Macchia, E., Torsi, L., Stefanachi, A., & Leonetti, F. (2026). PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives. Pharmaceuticals, 19(9), 1352. https://doi.org/10.3390/ph19091352

Vancouver

Degennaro P, Ghafir El Idrissi I, Purgatorio R, Fanizzi A, Rullo M, Pisani L, et al. PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives. Pharmaceuticals. 2026;19(9):1352. doi:10.3390/ph19091352

BibTeX
@article{Degennaro2026,
  author = {Degennaro, Pasquale and Ghafir El Idrissi, Imane and Purgatorio, Rosa and Fanizzi, Annalisa and Rullo, Mariagrazia and Pisani, Leonardo and Macchia, Eleonora and Torsi, Luisa and Stefanachi, Angela and Leonetti, Francesco},
  title = {PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {9},
  pages = {1352},
  doi = {10.3390/ph19091352}
}
Kostenlos starten →